| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $77,811,343 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 5 | NIH | 3/3/2026 | $674,251 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 001 | 4 | NIH | 4/16/2026 | $45,953 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 4 | NIH | 1/16/2026 | $413,593 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24CA224331 | Cancer Immune Monitoring and Analysis Center | 001 | 5 | NIH | 6/30/2026 | $1,934,873 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI179839 | High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis | 000 | 3 | NIH | 4/6/2026 | $813,272 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 001 | 5 | NIH | 4/16/2026 | $24,900 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 5 | NIH | 1/9/2026 | $224,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA284565 | Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities | 001 | 3 | NIH | 7/3/2026 | $2,539,029 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 001 | 6 | NIH | 4/16/2026 | $44,264 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 000 | 6 | NIH | 12/15/2025 | $398,378 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 3 | NIH | 2/9/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 000 | 31 | NIH | 2/12/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274706 | SIRT1 Regulates RNA Stability to Promote Breast Cancer | 000 | 5 | NIH | 5/12/2026 | $100,008 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 001 | 3 | NIH | 4/16/2026 | $67,440 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 3 | NIH | 2/24/2026 | $606,976 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 5 | NIH | 11/26/2025 | $1,164,461 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG013083 | Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease | 000 | 3 | NIH | 5/11/2026 | $502,740 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289547 | Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | 000 | 3 | NIH | 6/16/2026 | $677,174 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274597 | Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers. | 000 | 5 | NIH | 6/18/2026 | $102,773 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 5 | NIH | 4/16/2026 | $68,012 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 000 | 5 | NIH | 1/8/2026 | $612,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 004 | 4 | NIH | 4/17/2026 | $999 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 003 | 4 | NIH | 4/16/2026 | $39,691 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 002 | 4 | NIH | 1/30/2026 | $8,991 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 001 | 4 | NIH | 1/23/2026 | $350,562 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 001 | 3 | NIH | 2/23/2026 | $50,597 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 3 | NIH | 1/7/2026 | $455,377 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 000 | 10 | NIH | 3/25/2026 | $403,964 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG086369 | Mitoribosome protein translation signaling and survival mechanisms | 000 | 4 | NIH | 5/26/2026 | $727,340 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 000 | 3 | NIH | 4/8/2026 | $487,506 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 001 | 4 | NIH | 4/16/2026 | $56,177 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 002 | 1 | NIH | 4/24/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 001 | 1 | NIH | 3/27/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 000 | 1 | NIH | 3/9/2026 | $15,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142783 | Niche regulation of gastric epithelial cell differentiation | 000 | 1 | NIH | 3/19/2026 | $740,581 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35HL183474 | Elucidating the Origins and Drivers of Clonal Dynamics in Hematopoiesis | 000 | 1 | NIH | 3/10/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312664 | Structure-function and mechanistic studies of a specific glycosyltransferase complex in fusion-driven pediatric gliomas | 000 | 1 | NIH | 6/12/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303520 | Flipping the Switch in Cell Cycle Control: Dissecting the Molecular Mechanisms Governing Wee1 Kinase transition from Cdk Inhibitor to Substrate | 000 | 1 | NIH | 6/12/2026 | $645,102 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA311335 | USP1 inhibitor-mediated reversal of PARP inhibitor resistance in ovarian cancer. | 000 | 1 | NIH | 6/12/2026 | $463,279 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 001 | 1 | NIH | 2/27/2026 | $0 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 000 | 1 | NIH | 2/27/2026 | $78,040 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312809 | Defining epigenetic underpinnings of neuroendocrine lineage carcinomas | 000 | 1 | NIH | 6/30/2026 | $170,394 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA302918 | From biology to therapy: mechanism-informed targeting in translocation renal cell carcinoma | 000 | 1 | NIH | 6/30/2026 | $737,086 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300940 | The biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations | 000 | 1 | NIH | 4/27/2026 | $235,491 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA301574 | TIRR/53BP1 complex regulates mitotic fidelity and immune-mediated radiation response | 000 | 1 | NIH | 3/24/2026 | $683,075 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303334 | Context-specific pathway dependencies for nuclear envelope proteins in brain cancer | 000 | 1 | NIH | 6/25/2026 | $718,275 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA307630 | Establishing Ethical Standards for Informed Consent and Counseling for Multi-Cancer Early Detection Testing | 000 | 1 | NIH | 4/21/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AI200817 | Developmental Potential of IN-TACKs | 000 | 1 | NIH | 5/4/2026 | $267,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 3 | NIH | 4/16/2026 | $72,700 |
|
